Integer Holdings' (ITGR) 2019 View Strong Despite Rivalry

Zacks Investment Research | Feb 25, 2019 07:58AM ET

On Feb 22, we issued an updated research report on Integer Holdings Corporation (NYSE:ITGR) . A solid view for 2019 is working in favor of the company despite stiff rivalry in the MedTech space.

The stock currently carries a Zacks Rank #3 (Hold).

What’s Favoring the Stock?

Along with a solid fourth-quarter show, Integer Holdings issued a strong 2019 view.

Notably, adjusted earnings per share are expected within $4.05 to $4.25, indicating a rise of 7-12% from the previous year. Integer Holdings expects earnings per share in the $2.77 to $2.97 band on a reported basis, mirroring 7-12% growth year over year.

For 2019, Integer Holdings expects revenues between $1.26 billion and $1.28 billion, reflecting year-over-year growth of 4-5%. On an adjusted basis, the company expects revenues in the same band, showing growth of 4-6% from the previous year. Adjusted income from operations is anticipated between $141 million and $275 million, calling for a year-over-year rise of 8-13%.

Additionally, Integer Holdings has a stable footing in the cardiac, neuromodulation, orthopedics, vascular and advanced surgical markets.

In the recently-reported fourth quarter, Integer Holdings focused its sales efforts on increasing market penetration in the higher growth Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets. The company is also making strategic initiatives to maintain its leadership position in the cardiac rhythm management market.

Shares Up

Over the past year, shares of Integer Holdings have rallied 70% compared with the S&P 500 index’s 0.5% gain.

Deterrents

Integer Holdings earns a major portion of revenues from cardiac, neuromodulation, orthopedics, vascular, advanced surgical and power solutions markets. The company faces stiff competition in the MedTech space from players like Medtronic (NYSE:MDT) , Boston Scientific (NYSE:BSX), Stryker (NYSE:SYK) , Smith & Nephew (LON:SN) and ConvaTec.

Key Pick

A better-ranked stock from the Zacks Investment Research

Get The News You Want

Read market moving news with a personalized feed of stocks you care about.

Get The App

Written By: Zacks Investment Research

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Show moreShow Less